Scientists at the Fraunhofer Institute for Cell Therapies and Immunology (IZI) Leipzig, Germany, have developed an alternative to established antibiotics. In the future it will be possible to use antimicrobial peptides instead of ineffective antibiotics for combating pathogens.

Allergan Inc. (NYSE:AGN) got the approval for a fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX® (onabotulinumtoxinA) and BOTOX® Cosmetic from the United States Food and Drug Administration (FDA).

With "InLiveTox", a project supported by the European Union, scientists for the first time interconnect three biological barriers in one sigle "in vitro model". With that they want to simulate nature related conditions like in human body.

InvitroJobs will present scientists and their innovative research in a regular feature called “Working Group – a Portrait”. We will focus on newly developed methods, their evaluation and their potential for reducing and where possible replacing animal experimentation according to the 3R principle of Russel & Burch (reduce, refine, replace).
The series will continue with the research group "Experimental Cell- and Tissue Technology", which is within the working group "Molecular Haemostaseology" at the University Hospital of Jena. The presentation is followed by an interview with Dr. rer. nat Sandy Mosig.